Abstract
The incretin hormone glucagon-like peptide-1 (GLP-1) is a gut peptide with physiological functions such as insulin-releasing, gastric empty-delaying, body weight-lowering and appetite-reducing.However,due to the shortened half-life caused by enzymatic: deactivation from dipeptidyl peptidase-Ⅳ (DPP-Ⅳ), native GLP-1 has to be.administered continuously through intravenuus or injection to maintain its effectiveness.The complicated prerequisite hinders native GLP-1 to become a feasible glucose-lowering agent.Liraglutide is a once daily GLP-1 mimetic currently under development.While preserves the physiological trait of native GLP-1,liraglutide could sustain its clinical effect by binding to albumin thus prolong its metabolic time through its modified molecular structure.With its proved efficiency and safety in clinical studies and its various therapeutic etTect such as glucose metabolism regulation, β-eell function restoration, body weight loss and systolic pressure reduction,liraglutide is expected to bring a new hope to patients with type 2 diabetes mellitus. Key words: Diabetes mellitus; Glucagon like peptide-1 ; Analogue
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
